Albireo Pharma (NASDAQ:ALBO) Upgraded at ValuEngine

Albireo Pharma (NASDAQ:ALBO) was upgraded by investment analysts at ValuEngine from a “buy” rating to a “strong-buy” rating in a note issued to investors on Monday, April 1st, ValuEngine reports.

Several other equities analysts also recently commented on the stock. BidaskClub raised shares of Albireo Pharma from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 2nd. Zacks Investment Research downgraded shares of Albireo Pharma from a “hold” rating to a “sell” rating in a report on Monday, March 11th. Wedbush reissued a “buy” rating and issued a $69.00 target price on shares of Albireo Pharma in a report on Friday, January 25th. Finally, HC Wainwright started coverage on shares of Albireo Pharma in a report on Thursday, February 28th. They issued a “buy” rating and a $62.00 target price on the stock. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. Albireo Pharma presently has an average rating of “Buy” and a consensus price target of $54.25.

Shares of ALBO traded down $1.10 on Monday, reaching $30.80. The company’s stock had a trading volume of 28,127 shares, compared to its average volume of 36,403. The company has a market cap of $383.63 million, a price-to-earnings ratio of -7.82 and a beta of 1.72. Albireo Pharma has a 12-month low of $19.10 and a 12-month high of $37.95.

Albireo Pharma (NASDAQ:ALBO) last posted its quarterly earnings data on Thursday, March 7th. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.18). Albireo Pharma had a negative return on equity of 32.42% and a negative net margin of 361.94%. The business had revenue of $0.57 million during the quarter, compared to analysts’ expectations of $1.94 million. As a group, research analysts predict that Albireo Pharma will post -5.74 EPS for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in ALBO. Wells Fargo & Company MN lifted its holdings in shares of Albireo Pharma by 315.3% in the third quarter. Wells Fargo & Company MN now owns 4,676 shares of the biopharmaceutical company’s stock worth $154,000 after buying an additional 3,550 shares in the last quarter. Prudential Financial Inc. increased its position in Albireo Pharma by 9.0% in the third quarter. Prudential Financial Inc. now owns 25,152 shares of the biopharmaceutical company’s stock worth $829,000 after purchasing an additional 2,075 shares during the last quarter. Bank of New York Mellon Corp increased its position in Albireo Pharma by 8.6% in the third quarter. Bank of New York Mellon Corp now owns 35,023 shares of the biopharmaceutical company’s stock worth $1,154,000 after purchasing an additional 2,760 shares during the last quarter. BlackRock Inc. increased its position in Albireo Pharma by 11.4% in the third quarter. BlackRock Inc. now owns 584,177 shares of the biopharmaceutical company’s stock worth $19,255,000 after purchasing an additional 59,901 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its position in Albireo Pharma by 518.1% in the third quarter. Dimensional Fund Advisors LP now owns 82,833 shares of the biopharmaceutical company’s stock worth $2,730,000 after purchasing an additional 69,431 shares during the last quarter. 66.85% of the stock is currently owned by hedge funds and other institutional investors.

Albireo Pharma Company Profile

Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate is A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.

Recommended Story: Return on Investment (ROI) Defined, Explained

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.